{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:35:11Z","timestamp":1789097711937,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AIFA","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chronic hypoparathyroidism is usually treated with calcium and active vitamin D metabolites or analogs, despite the fact that their chronic use can lead to long-term complications. The use of hormone replacement therapy with PTH peptides [teriparatide and rhPTH (1\u201384)] has therefore been proposed. The main purpose of this study was to investigate the efficacy of teriparatide dose at 20\u2009\u00b5g once or twice daily, in order to maintain normocalcemia reducing standard treatment, in adult patients with chronic hypoparathyroidism not well controlled with conventional treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study was a Phase III, open-label, non-comparative, clinical investigation (study period: 3 months), at a tertiary care clinical research center. Thirty patients with chronic hypoparathyroidism were screened, and 12 started teriparatide. After the optimization phase (0\u20134 weeks), calcium and calcitriol supplements were progressively reduced, while teriparatide 20\u2009\u00b5g once daily was administered (5\u20137 weeks), and then could be titrated up to 20\u2009\u00b5g twice daily (7\u201317 weeks). The main outcome measures included serum and urinary biochemical exams and Rand 36-Item Short Form Health Survey.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study showed that teriparatide 20\u2009\u00b5g once daily was insufficient to discontinue calcium and calcitriol supplements to maintain normal serum calcium concentrations. Conversely, for more than half of patients treated with teriparatide 20\u2009\u00b5g twice daily, calcium and calcitriol administration was avoidable, but in some cases at the expense of serum calcium and phosphate oscillations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Since intervention trials evaluating the efficacy and safety of teriparatide in hypoparathyroid patients are not yet available, the routine use of this molecule poses some doubts.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-020-02577-x","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T06:03:20Z","timestamp":1612418600000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Chronic hypoparathyroidism and treatment with teriparatide"],"prefix":"10.1007","volume":"72","author":[{"given":"Gemma","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Cianferotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Fossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Parri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2577_CR1","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"J.P. Bilezikian, A. Khan, J.T. Potts Jr. et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Min. Res. 26, 2317\u20132337 (2011)","journal-title":"J. Bone Min. Res."},{"key":"2577_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"M.L. Brandi, J.P. Bilezikian, D. Shoback et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273\u20132283 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"J.P. Bilezikian, M.L. Brandi, N.E. Cusano, M. Mannstadt, L. Rejnmark, R. Rizzoli, M.R. Rubin, K.K. Winer, U.A. Liberman, J.T. Potts Jr, Management of hypoparathyroidism: present and future. J. Clin. Endocrinol. Metab. 101, 2313\u20132324 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000491046","volume":"51","author":"G Marcucci","year":"2019","unstructured":"G. Marcucci, M.L. Brandi, Conventional treatment of hypoparathyroidism. Front Horm. Res 51, 160\u2013164 (2019)","journal-title":"Front Horm. Res"},{"key":"2577_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1172\/JCI110372","volume":"68","author":"DM Slovik","year":"1981","unstructured":"D.M. Slovik, R.M. Neer, J.T. Potts, Short-term effects of synthetic human parathyroid hormone 1\u201334 administration on bone mineral metabolism in osteoporotic patients. J. Clin. Invest. 68, 1261\u2013127 (1981)","journal-title":"J. Clin. Invest."},{"key":"2577_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jbmr.5650010411","volume":"1","author":"DM Slovik","year":"1986","unstructured":"D.M. Slovik, D.I. Rosenthal, S.H. Doppelt et al. Restoration of spinal bone in osteoporotic men by treatment with parathyroid hormone 1\u201334 and 1,25 dihydroxyvitamin D. J. Bone Min. Res. 1, 377\u2013381 (1986)","journal-title":"J. Bone Min. Res."},{"key":"2577_CR7","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","volume":"331","author":"JS Finkelstein","year":"1994","unstructured":"J.S. Finkelstein, A. Kibanski, E.H. Schaefer et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 331, 1618\u20131623 (1994)","journal-title":"N. Engl. J. Med."},{"key":"2577_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"D.L. Kendler, F. Marin, C.A.F. Zerbini et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391, 230\u2013240 (2018)","journal-title":"Lancet"},{"key":"2577_CR9","doi-asserted-by":"crossref","unstructured":"B.L. Langdahl, S. Silverman, S. Fujiwara, et al. Real-world effeccin patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone 116, 58\u201366 (2018)","DOI":"10.1016\/j.bone.2018.07.013"},{"key":"2577_CR10","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1210\/jc.2002-021736","volume":"88","author":"KK Winer","year":"2003","unstructured":"K.K. Winer, C.W. Ko, J.C. Reynolds et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 88, 4214\u20134220 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","volume":"165","author":"KK Winer","year":"2014","unstructured":"K.K. Winer, K. Fulton, P.A. Culter, G. Cutler, Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J. Pediatr. 165, 556\u2013563 (2014)","journal-title":"J. Pediatr."},{"key":"2577_CR12","first-page":"3480","volume":"83","author":"KK Winer","year":"1998","unstructured":"K.K. Winer, J.A. Yanovski, B. Sarani, G.B. Cutler Jr, A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone1\u201334 in treatment of hypoparathyroidism. J. Clin. Endocrinol. Metab. 83, 3480\u20133486 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","volume":"276","author":"KK Winer","year":"1996","unstructured":"K.K. Winer, J.A. Yanovski, G.B. Cutler Jr, Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276, 631\u2013636 (1996)","journal-title":"JAMA"},{"key":"2577_CR14","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1210\/jc.2009-2464","volume":"95","author":"KK Winer","year":"2010","unstructured":"K.K. Winer, N. Sinaii, J. Reynolds et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 95, 2680\u20132688 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR15","first-page":"391","volume":"97","author":"KK Winer","year":"2012","unstructured":"K.K. Winer, B. Zhang, J.A. Shrader et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97, 391\u2013399 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"R.M. Neer, C.D. Arnaud, J.R. Zanchetta et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434\u20131441 (2001)","journal-title":"N. Engl. J. Med."},{"key":"2577_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"J.L. Vahle, M. Sato, G.G. Long et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30, 312\u2013321 (2002)","journal-title":"Toxicol. Pathol."},{"key":"2577_CR18","unstructured":"FDA. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021318s012lbl.pdf (2002)"},{"key":"2577_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1345\/aph.1D353","volume":"38","author":"KA Cappuzzo","year":"2004","unstructured":"K.A. Cappuzzo, J.C. Delafuente, Teriparatide for severe osteoporosis. Ann. Pharmacother. 38, 294\u2013302 (2004)","journal-title":"Ann. Pharmacother."},{"key":"2577_CR20","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1210\/jc.2015-1855","volume":"100","author":"A Santonati","year":"2015","unstructured":"A. Santonati, A. Palermo, E. Maddaloni et al. PTH (1\u201334) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J. Clin. Endocrinol. Metab. 100, 3590\u20133597 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1210\/jc.2017-01555","volume":"103","author":"A Palermo","year":"2018","unstructured":"A. Palermo, A. Santonati, G. Tabacco, D. Bosco, A. Spada, C. Pedone, B. Raggiunti, T. Doris, D. Maggi, F. Grimaldi, S. Manfrini, F. Vescini, PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J. Clin. Endocrinol. Metab. 103, 271\u2013280 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"S.L. Greenspan, H.G. Bone, M.P. Ettinger et al. Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326\u2013339 (2007)","journal-title":"Ann. Intern. Med."},{"key":"2577_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1185\/03007995.2012.659724","volume":"28","author":"A Migliore","year":"2012","unstructured":"A. Migliore, S. Broccoli, U. Massafra et al. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis. Curr. Med. Res. Opin. 28, 467\u2013473 (2012)","journal-title":"Curr. Med. Res. Opin."},{"key":"2577_CR24","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","volume":"16","author":"G Marcucci","year":"2016","unstructured":"G. Marcucci, G.D. Pepa, M.L. Brandi, Natpara for the treatment of hypoparathyroidism. Expert Opin. Biol. Ther. 16, 1417\u20131424 (2016)","journal-title":"Expert Opin. Biol. Ther."},{"key":"2577_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"N.E. Cusano, M.R. Rubin, D.J. McMahon et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 98, 137\u2013144 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4158\/EP15936.OR","volume":"22","author":"P Lakatos","year":"2016","unstructured":"P. Lakatos, L. Bajnok, H. Lagast, Z. Valkusz, An open-label extension study of parathyroid hormone rhPTH(1\u201384) in adults with hypoparathyroidism. Endocr. Pr. 22, 523\u2013532 (2016)","journal-title":"Endocr. Pr."},{"key":"2577_CR27","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1210\/jc.2015-4135","volume":"101","author":"MR Rubin","year":"2016","unstructured":"M.R. Rubin, N.E. Cusano, W.W. Fan et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 101, 2742\u20132750 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","volume":"55","author":"BL Clarke","year":"2017","unstructured":"B.L. Clarke, T.J. Vokes, J.P. Bilezikian, D.M. Shoback, H. Lagast, M. Mannstadt, Effects of parathyroid hormone rhPTH(1\u201384) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine 55, 273\u2013282 (2017)","journal-title":"Endocrine"},{"key":"2577_CR29","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1210\/jc.2014-2267","volume":"99","author":"NE Cusano","year":"2014","unstructured":"N.E. Cusano, M.R. Rubin, D.J. McMahon et al. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J. Clin. Endocrinol. Metab. 99, 3694\u20133699 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR30","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"T. Sikjaer, L. Rolighed, A. Hess, A. Fuglsang-Frederiksen, L. Mosekilde, L. Rejnmark, Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos. Int. 25, 1717\u20131726 (2014)","journal-title":"Osteoporos. Int."},{"key":"2577_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"T.J. Vokes, M. Mannstadt, M.A. Levine, B.L. Clarke, P. Lakatos, K. Chen, R. Piccolo, A. Krasner, D.M. Shoback, J.P. Bilezikian, Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 103, 722\u2013731 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR32","unstructured":"Shire-NPS Pharmaceuticals, Inc. Natpara (parathyroid hormone). Full Prescribing Information (Shire-NPS Pharmaceuticals, Inc., Lexington, MA, 2016)"},{"key":"2577_CR33","unstructured":"Natpara [package insert]. (NPS Pharmaceuticals, Inc, Bedminster, NJ, 2015)"},{"key":"2577_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","volume":"16","author":"G Marcucci","year":"2016","unstructured":"G. Marcucci, G.D. Pepa, M.L. Brandi, Natpara for the treatment of hypoparathyroidism. Expert Opin. Biol. Ther. 16, 1417\u20131424 (2016)","journal-title":"Expert Opin. Biol. Ther."},{"key":"2577_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14740338.2017.1311322","volume":"16","author":"G Marcucci","year":"2017","unstructured":"G. Marcucci, G.D. Pepa, M.L. Brandi, Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. Expert Opin. Drug Saf. 16, 617\u2013625 (2017)","journal-title":"Expert Opin. Drug Saf."},{"key":"2577_CR36","unstructured":"European Medicines Agency. Natpar (parathyroid hormone) EMA Summary of Product Characteristics (EMA, 2017). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003861\/WC500226450.pdf"},{"key":"2577_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391\u2013403 (2008)","journal-title":"N. Engl. J. Med."},{"key":"2577_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00223-018-0411-7","volume":"103","author":"G Marcucci","year":"2018","unstructured":"G. Marcucci, L. Cianferotti, S. Parri et al. HypoparaNet: a database of chronic hypoparathyroidism based on expert medical-surgical centers in Italy. Calcif. Tissue Int. 103, 151\u2013163 (2018)","journal-title":"Calcif. Tissue Int."},{"key":"2577_CR39","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","volume":"41","author":"A Meola","year":"2018","unstructured":"A. Meola, E. Vignali, A. Matrone et al. Efficacy and safety of long-term management of patients with chronic post surgical hypoparathyroidism. J. Endocrinol. Invest. 41, 1221\u20131226 (2018)","journal-title":"J. Endocrinol. Invest."},{"key":"2577_CR40","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1210\/jc.2015-3909","volume":"101","author":"DM Shoback","year":"2016","unstructured":"D.M. Shoback, J.P. Bilezikian, A.G. Costa et al. Presentation of hypoparathyroidism: etiologies and clinical features. J. Clin. Endocrinol. Metab. 101, 2300\u20132312 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bone.2018.09.017","volume":"120","author":"T Vokes","year":"2019","unstructured":"T. Vokes, Quality of life in hypoparathyroidism. Bone 120, 542\u2013547 (2019)","journal-title":"Bone"},{"key":"2577_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"W. Arlt, C. Fremerey, F. Callies, Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receving standard treatment with calcium and vitamin D. Eur. J. Endocrinol. 146, 215\u2013222 (2002)","journal-title":"Eur. J. Endocrinol."},{"key":"2577_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"M. Mannstadt, B.L. Clarke, T. Vokes et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 1, 275\u2013283 (2013)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2577_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4158\/EP15936.OR","volume":"22","author":"P Lakatos","year":"2016","unstructured":"P. Lakatos, L. Bajnok, H. Lagast et al. An open-label extension study of parathyroid hormone rhPTH(1\u201384) in adults with hypoparathyroidism. Endocr. Pr. 22, 523\u2013532 (2016)","journal-title":"Endocr. Pr."},{"key":"2577_CR45","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1002\/jbmr.452","volume":"26","author":"MR Rubin","year":"2011","unstructured":"M.R. Rubin, D.W. Dempster, J. Sliney Jr. et al. PTH (1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J. Bone Min. Res. 26, 2727\u20132736 (2011)","journal-title":"J. Bone Min. Res."},{"key":"2577_CR46","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"M.L. Brandi, J.P. Bilezikian, D. Shoback et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273\u20132283 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR47","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"J. Bollerslev, L. Rejnmark, C. Marcocci et al. European Society of Endocrinology, European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173, G1\u2013G20 (2015)","journal-title":"Eur. J. Endocrinol."},{"key":"2577_CR48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","volume":"86","author":"J Jolette","year":"2017","unstructured":"J. Jolette, B. Attalla, A. Varela et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul. Toxicol. Pharm. 86, 356\u2013365 (2017)","journal-title":"Regul. Toxicol. Pharm."},{"key":"2577_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00223-016-0222-7","volume":"100","author":"C Cipriani","year":"2017","unstructured":"C. Cipriani, J. Pepe, F. Biamonte, R. Manai et al. The epidemiology of hypoparathyroidism in Italy: an 8-Year Register-Based Study. Calcif. Tissue Int 100, 278\u2013285 (2017)","journal-title":"Calcif. Tissue Int"},{"key":"2577_CR50","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/01926230601072301","volume":"34","author":"J Jolette","year":"2006","unstructured":"J. Jolette, C.E. Wilker, S.Y. Smith et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol. Pathol. 34, 929\u2013940 (2006)","journal-title":"Toxicol. Pathol."},{"key":"2577_CR51","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"E.B. Andrews, A.W. Gilsenan, K. Midkiff et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Min. Res. 27, 2429\u20132437 (2012)","journal-title":"J. Bone Min. Res."},{"key":"2577_CR52","unstructured":"EMA. https:\/\/www.ema.europa.eu\/documents\/product-information\/natpar-epar-product-information-en.pdf (2019)"},{"key":"2577_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00223-018-0405-5","volume":"103","author":"L Cianferotti","year":"2018","unstructured":"L. Cianferotti, S. Parri, G. Gronchi, G. Marcucci et al. Prevalence of chronic hypoparathyroidism in a Mediterranean region as estimated by the analysis of anonymous healthcare database. Calcif. Tissue Int. 103, 144\u2013150 (2018)","journal-title":"Calcif. Tissue Int."},{"key":"2577_CR54","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.beem.2018.07.001","volume":"32","author":"L Cianferotti","year":"2018","unstructured":"L. Cianferotti, G. Marcucci, M.L. Brandi, Causes and pathophysiology of hypoparathyroidism. Best. Pr. Res. Clin. Endocrinol. Metab. 32, 909\u2013925 (2018)","journal-title":"Best. Pr. Res. Clin. Endocrinol. Metab."},{"key":"2577_CR55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.beem.2018.09.007","volume":"32","author":"G Marcucci","year":"2018","unstructured":"G. Marcucci, L. Cianferotti, M.L. Brandi, Clinical presentation and management of hypoparathyroidism. Best. Pr. Res. Clin. Endocrinol. Metab. 32, 927\u2013939 (2018)","journal-title":"Best. Pr. Res. Clin. Endocrinol. Metab."},{"key":"2577_CR56","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/jbmr.2004","volume":"28","author":"J Powers","year":"2013","unstructured":"J. Powers, K. Joy, A. Ruscio, H. Lagast, Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J. Bone Min. Res. 28, 2570\u20132576 (2013)","journal-title":"J. Bone Min. Res."},{"key":"2577_CR57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00405-014-3484-6","volume":"273","author":"Y Ramakrishnan","year":"2016","unstructured":"Y. Ramakrishnan, H.C. Cocks, Impact of recombinant PTH on management of hypoparathyroidism: a systematic review. Eur. Arch. Otorhinolaryngol. 273, 827\u2013835 (2016)","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"2577_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"J Sliney Jr.","year":"2013","unstructured":"J. Sliney Jr., S.C. Cremers, J.P. Bilezikian, Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 98, 137\u2013144 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2577_CR59","first-page":"123","volume":"30","author":"AG Bag\u00f3","year":"2008","unstructured":"A.G. Bag\u00f3, M. Palkovits, T.B. Usdin, L. Seress, A. Dobolyi, Evidence for the expression of parathyroid hormone 2 receptor in the human brainstem. Ideggyogy. Sz. 30, 123\u2013126 (2008)","journal-title":"Ideggyogy. Sz."},{"key":"2577_CR60","unstructured":"NIH. A registry for participants with chronic hypoparathyroidism (PARADIGHM). ClinicalTrials.gov Identifier: NCT01922440. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01922440 (2020)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02577-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T23:25:39Z","timestamp":1674948339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02577-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02577-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The funding note for open access added.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.L.B. is a consultant for Alexion, Bruno Farmaceutici, Shire, Servier, Kyowa Kirin; academic grants and\/or speaker: Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire, SPA; she has received honoraria from Amgen, Bruno Farmaceutici, Kyowa Kirin. L.C. received speaking fees from Bruno Farmaceutici, Abiogen Pharma, Shire, Sandoz; she is a consultant for UCB. The remaining authors declare that they have no conflicts of interest or disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Investigator Board of the University Hospital of Florence and AIFA (Code-EUDRACT:2013-001890-26). All subjects participating in the study signed an informed consent form, and all personal, clinical, and biological data were collected in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\/publication"}}]}}